159 related articles for article (PubMed ID: 37601678)
1. Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports.
Jin Y; Xu J; Zhuang D; Dong L; Sun Y; Zhao L; Xiao W
Front Oncol; 2023; 13():1221309. PubMed ID: 37601678
[TBL] [Abstract][Full Text] [Related]
2. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
7. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
8. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis.
Zhao M; Shao T; Ren Y; Zhou C; Tang W
Front Pharmacol; 2022; 13():910656. PubMed ID: 36249794
[No Abstract] [Full Text] [Related]
9. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
[TBL] [Abstract][Full Text] [Related]
10. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
Wei Z; Yang X; Ye X; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zou Z; Wen Q
J Cancer Res Ther; 2019; 15(7):1629-1634. PubMed ID: 31939448
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic Ultrasound-Guided Ethanol Injection Associated with Trans-arterial Embolization of a Giant Intra-abdominal Cavernous Hemangioma: Case Report and New Therapeutic Option.
Ferreira FG; Ribeiro MA; Abreu P; Ferreira R; Assef MS; Park JH; Szutan LA
J Gastrointest Cancer; 2021 Mar; 52(1):381-385. PubMed ID: 33411258
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Ni J; Si X; Wang H; Zhang X; Zhang L
Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety.
Cao H; Wei W; Lu Y
J Clin Pharm Ther; 2022 Nov; 47(11):1775-1782. PubMed ID: 35851702
[TBL] [Abstract][Full Text] [Related]
18. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).
Wang R; Shi M; Ji M; Han Z; Chen L; Liu Y; Lu K; Liu L; Chen B; Zhang X; Miao L; Shu Y
Transl Lung Cancer Res; 2023 Apr; 12(4):786-796. PubMed ID: 37197631
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Salous T; Shukla NA; Althouse SK; Perkins SM; Furqan M; Leal T; Traynor AM; Feldman LE; Hanna NH; Durm GA
Cancer; 2023 Jan; 129(2):264-271. PubMed ID: 36420773
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C;
J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
